Typbar TCV ® is a Typhoid Vi Capsular Polysaccharide Tetanus Toxoid Conjugate vaccine. The Typhoid Vi Capsular Polysaccharide Tetanus Toxoid Conjugate vaccine stimulates specialized T cells in the human body, which the Typhoid Vi Capsular Polysaccharide vaccine alone cannot do. Engagement of T cells by Vi conjugate vaccine results in superior and longer lasting antibody response, which helps in the prevention of typhoid disease not only in adults but also in children and infants.
Typbar TCV® is the world’s 1st clinically proven conjugate Typhoid vaccine. Further, the Typhoid Vi Capsular Polysaccharide Tetanus Toxoid Conjugate vaccine is the only approved vaccine for children and infants less than 2 years of age.
During the Phase III clinical study, a single dose of Typbar TCV elicited 4-fold seroconversion rates of 98.05%, 99.17% and 92.13% in subjects between ≥6 months to 2 years, ˃2 to 15 years and ˃15 to 45 years respectively.Results of this study has been published in Clinical infectious Diseases.
Results from a human challenge study carried out at Oxford University have demonstrated that the vaccine is safe, 100% immunogenic, and prevents up to 87% of infections, when using real life definitions of typhoid fever.
TYPBAR-TCV has been recommended by WHO-Strategic Advisory Group of Experts for routine immunizations.